CBMG Biotech Completes $410 Million Privatization Led by Yunfeng Capital Consortium

On February 20 (Beijing time), Cellular Biomedicine Group (NASDAQ: CBMG, hereinafter referred to as “CBMG”) announced the completion of its privatization transaction initiated by a buyer consortium led by YF Capital, TF Capital, and CEO Liu Bizuo.

According to the announcement, the cash consideration per share paid by the buyer consortium was $19.75, with a total transaction valuation of approximately $410 million. In addition to YF Capital and TF Capital, the institutional investors participating in this transaction included several other well-known investment firms, such as the Government of Singapore Investment Corporation (GIC).

Regarding this transaction, Yu Feng, Co-founder and Chairman of YF Capital, stated: “Over the past decade, China’s pharmaceutical industry has been transitioning from the 1.0 era dominated by generic drugs, through the 2.0 era characterized by rapid follow-on development or introduction of overseas novel targets, toward the 3.0 era of globalized innovation. As an innovative therapy following targeted drugs and biologics, cell therapy will lead the next generation of therapeutic innovations. We are honored to have led the buyer consortium in participating in this transaction and completing the privatization of Cellular Biomedicine Group (Shanghai) Ltd. YF Capital will continue to support and monitor the company’s development, helping it become an innovative cell therapy platform rooted in China and serving the global market.”

Liu Bizuo, CEO of Cellular Biomedicine Group (CBMG), stated: “As a platform company in the field of cell therapy, CBMG has established layouts across four major technological platforms: single/multi-target CAR-T, TCR-T, TIL, and stem cells, and has already achieved some positive trial results. The company boasts an international R&D team and platform, is committed to technical cooperation between China and the United States, and has gained recognition from leading global CAR-T cell therapy pharmaceutical companies, establishing strategic partnerships with them. We are honored to collaborate with renowned investment institutions such as YF Capital and TF Capital, which will enable us to leverage capital strength for accelerated development. We remain optimistic about the innovative trends in cell therapy technology and are dedicated to becoming an internationally leading innovative cell therapy platform, integrating advanced technologies from both domestic and international sources to serve patients worldwide.”

Cellular Biomedicine Group was officially listed on the NASDAQ in the United States in 2014, becoming the first Chinese cell therapy biotechnology company to be listed on the NASDAQ. Upon completion of this privatization, YF Capital will leverage its unique ecosystem advantages to comprehensively empower Cellular Biomedicine Group, helping it become the most competitive innovative cell therapy platform and benefiting more patients in China.

In recent years, YF Capital has not only established a series of in-depth collaborations with leading domestic and international healthcare enterprises through its investments across the upstream and downstream segments of the medical and health industry, but also achieved full-industry-chain layout in multiple niche markets, including biopharmaceuticals, CXO, medical devices, and healthcare services.

YF Capital’s portfolio companies in the healthcare sector include well-known domestic and international platform-based and innovative enterprises such as Alibaba Health, iKang Healthcare Group, Meinian Onehealth Healthcare, and WuXi AppTec. YF Capital will accelerate the co-development of a healthcare industry ecosystem with leading healthcare institutions, introduce advanced overseas technologies and expertise, and boost the growth of China’s healthcare industry.